Back to Search Start Over

Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS

Authors :
Xing Wang
Natasha Raman
Ghali Lemtiri-Chlieh
Jinhee Chang
Shreya Jagtap
Dipanwita Dutta Chowdhury
Matthew Ballew
Francesca Anna Carrieri
Triet Nguyen
Katriana Nugent
Travis Peck
Michelle S. Levine
Aaron Chan
Christine Lam
Reem Malek
Tung Hoang
Ryan Phillips
ZhuoAn Cheng
Kekoa Taparra
Nick Connis
Christine L. Hann
Andrew Holland
Phuoc T. Tran
Audrey Lafargue
Hailun Wang
Source :
Molecular Cancer Therapeutics. 22:519-528
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Extra copies of centrosomes are frequently observed in cancer cells. To survive and proliferate, cancer cells have developed strategies to cluster extra-centrosomes to form bipolar mitotic spindles. The aim of this study was to investigate whether centrosome clustering (CC) inhibition (CCi) would preferentially radiosensitize non–small cell lung cancer (NSCLC). Griseofulvin (GF; FDA-approved treatment) inhibits CC, and combined with radiation treatment (RT), resulted in a significant increase in the number of NSCLC cells with multipolar spindles, and decreased cell viability and colony formation ability in vitro. In vivo, GF treatment was well tolerated by mice, and the combined therapy of GF and radiation treatment resulted in a significant tumor growth delay. Both GF and radiation treatment also induced the generation of micronuclei (MN) in vitro and in vivo and activated cyclic GMP-AMP synthase (cGAS) in NSCLC cells. A significant increase in downstream cGAS-STING pathway activation was seen after combination treatment in A549 radioresistant cells that was dependent on cGAS. In conclusion, GF increased radiation treatment efficacy in lung cancer preclinical models in vitro and in vivo. This effect may be associated with the generation of MN and the activation of cGAS. These data suggest that the combination therapy of CCi, radiation treatment, and immunotherapy could be a promising strategy to treat NSCLC.

Subjects

Subjects :
Cancer Research
Oncology

Details

ISSN :
15388514 and 15357163
Volume :
22
Database :
OpenAIRE
Journal :
Molecular Cancer Therapeutics
Accession number :
edsair.doi...........c109ad13608c562d8b330269ae2aa510